In 2025, changes in US funding and support affected a range of global health research efforts, disrupting the course of ongoing work in the United States and around the world.
This interactive tool documents a selection of those projects, illustrating the scientific, economic, and human impacts. Explore the map and table below to learn more. Click on a location or use the table filters to view individual project details. Use the map controls to zoom and pan the map.
Map Key:
NIH
USAID
BARDA
Impact
Locations(s)
US Funder
Health Area(s)
Read More
A BARDA-funded project to develop a needle-free, intranasal COVID-19 vaccine appears discontinued, halting a promising approach to broader protection and slowing future vaccine innovation.
— Information current as of March 2026
Location(s):
Farmingdale, NY US Funder: BARDA
Health Area(s): COVID-19
NIH’s termination of the CREID network halted A2CARES, a multi-country research effort to detect and response to dengue, Zika, and other arboviruses across the Americas and Asia.
— Information current as of March 2026
Location(s):
Berkeley, CAChapel Hill, NC
Ann Arbor, MI
Atlanta, GA
San Francisco, CA
New York, NY
Ecuador
Nicaragua
Sri Lanka
US Funder: NIH
Health Area(s): Other emerging infectious diseases
The sudden cancellation of an NIH-funded Tulane research program cut short vital long COVID studies and derailed early-career scientists, leaving major gaps in understanding a condition affecting millions.
— Information current as of February 2026
Location(s):
New Orleans, LA US Funder: NIH
Health Area(s): COVID-19
The early termination of an NIH grant at the University of Alabama halted a near-complete study on COVID-19 in immunocompromised children, leaving years of research and investment without results that could have improved the care of vulnerable children.
— Information current as of April 2026
Location(s):
Birmingham, AL US Funder: NIH
Health Area(s): COVID-19
NIH’s termination of the CREID network ended CREATE-NEO, disrupting early‑warning surveillance and modeling for arboviral threats like Zika and dengue in Central and South America
— Information current as of March 2026
Location(s):
Galveston, TXMillbrook, NY
Cambridge, MA
University Park, NJ
Brazil
Panama
US Funder: NIH
Health Area(s): Other emerging infectious diseases
NIH’s termination of the CREID network ended CREID-ECA, a program to rapidly detect and respond to disease like Rift Valley fever and MERS in East and Central Africa.
— Information current as of March 2026
Location(s):
Pullman, WAAtlanta, GA
St. Louis, MO
Germany
Belgium
Democratic Republic of Congo
Kenya
Tanzania
Uganda
US Funder: NIH
Health Area(s): Other emerging infectious diseases
NIH’s termination of the CREID network ended CREID-ESP, halting a coordinated program to detect emerging infectious diseases early and speed outbreak response.
— Information current as of March 2026
Location(s):
St. Louis, MOLa Jolla, CA
Ethiopia
Republic of Korea
Nepal
Hong Kong
US Funder: NIH
Health Area(s): Other emerging infectious diseases
The loss of NIH diversity supplements at UC Berkeley disrupted research on infectious disease spillover and reduced training opportunities for future scientists.
— Information current as of April 2026
Location(s):
Berkeley, CA US Funder: NIH
Health Area(s): Other emerging infectious diseases
NIH’s termination of the CREID network ended EpiCenter, a global effort to improve detection and response to emerging viruses at the forest-human interface in high-risk regions.
— Information current as of March 2026
Location(s):
Davis, CAAtlanta, GA
Fort Collins, CO
Uganda
Peru
US Funder: NIH
Health Area(s): Other emerging infectious diseases
The loss of an NIH supplement at the University of Pittsburgh disrupted research on antibiotic-resistant infections and limited a key pathway for training early-career scientists.
— Information current as of July 2026
Location(s):
Pittsburgh, PA US Funder: NIH
Health Area(s): Antimicrobial resistance
The termination of an NIH diversity supplement at UT Southwestern Medical Center ended support for a graduate student, forcing layoffs and slowing research on viruses linked to shingles and cancer.
— Information current as of March 2026
Location(s):
Dallas, TX US Funder: NIH
Health Area(s): Neglected tropical diseases, Women's health/reproductive health
A major NIH-funded study on COVID-19 immunity at Ohio State was terminated early, limiting insights crucial for next-generation vaccines and future outbreak response.
— Information current as of March 2026
Location(s):
Columbus, OH US Funder: NIH
Health Area(s): COVID-19
The termination of an NIH diversity supplement at UT Health Houston disrupted both research on major parasitic disease and a key pathway for training early-career scientists.
— Information current as of April 2026
Location(s):
Houston, TX US Funder: NIH
Health Area(s): Neglected tropical diseases
NIH’s termination of the CREID network ended PICREID, a cross-country effort to track high-risk viruses and strengthen outbreak response across West and Central Africa and Southeast Asia.
— Information current as of March 2026
Location(s):
FranceCameroon
Thailand
Japan
Senegal
Cambodia
Canada
Turkey
Germany
US Funder: NIH
Health Area(s): Other emerging infectious diseases
An NIH grant termination at UTMB shut down support for a world-leading virus repository, weaking a critical national and global resource for responding to future outbreaks.
— Information current as of April 2026
Location(s):
Galveston, TX US Funder: NIH
Health Area(s): Other emerging infectious diseases
NIH’s termination of the CREID network ended UWARN, a multinational network aimed at preparing for future pandemics by advancing viral countermeasures.
— Information current as of March 2026
Location(s):
Seattle, WANew York, NY
Minneapolis, MN
Pakistan
Taiwan
Brazil
Switzerland
South Africa
Senegal
US Funder: NIH
Health Area(s): Other emerging infectious diseases
NIH’s termination of the CREID network ended WAC-EID, disrupting risk mapping of threats like Lassa, Ebola, dengue, and Zika and partnerships supporting West African regional outbreak response.
— Information current as of March 2026
Location(s):
Galveston, TXDavis, CA
Nigeria
Senegal
Sierra Leone
Singapore
Argentina
US Funder: NIH
Health Area(s): Other emerging infectious diseases
NIH’s termination of the CREID network ended WARN-ID, disrupting West Africa–US early-warning surveillance for high-consequence viral threats like Lassa fever.
— Information current as of March 2026
Location(s):
La Jolla, CACambridge, MA
New Orleans, LA
Liberia
Sierra Leone
Nigeria
Senegal
US Funder: NIH
Health Area(s): Other emerging infectious diseases
Termination of a major USAID-funded African HIV vaccine program halted a multi-country trial weeks before launch, wasting years of preparation and limiting expected scientific results.
— Information current as of April 2026
Location(s):
Seattle, WADurham, NC
Cambridge, MA
South Africa
Nigeria
Uganda
Kenya
Tanzania
Zimbabwe
Zambia
Mozambique
US Funder: USAID
Health Area(s): HIV/AIDS
A decades-long USAID–Army partnership that helped develop malaria vaccines was terminated, halting progress on a promising next-generation candidate.
— Information current as of March 2026
Location(s):
Silver Spring, MD US Funder: USAID
Health Area(s): Malaria
A canceled USAID grant ended work on promising user-centered contraceptive innovations, including a first-in-class biodegradable implant nearing human trials.
— Information current as of March 2026
Location(s):
Norfolk, VAKenya
US Funder: USAID
Health Area(s): Women's health/reproductive health
Cancellation of a USAID-funded HIV initiative stopped studies midstream and undermined efforts to end the epidemic through new vaccines and improved prevention approaches.
— Information current as of April 2026
Location(s):
New York, NYJersey City, NJ
La Jolla, CA
Rwanda
Kenya
South Africa
Zambia
Uganda
India
US Funder: USAID
Health Area(s): HIV/AIDS, Women's health/reproductive health
A USAID-funded HIV prevention project to improve PrEP adherence among young women was terminated early, delaying critical research findings.
— Information current as of March 2026
Location(s):
Norfolk, VATallahassee, FL
Aurora, CA
Pullman, WA
Foster City, CA
South Africa
Zimbabwe
US Funder: USAID
Health Area(s): HIV/AIDS, Women's health/reproductive health
The abrupt end of a USAID-funded HIV research program disrupted studies across multiple countries, eroded trust with partners, and set back progress on women-controlled prevention tools.
— Information current as of March 2026
Location(s):
Pittsburgh, PANew York, NY
Jersey City, NJ
La Jolla, CA
Durham, NC
Washington, DC
Chicago, IL
Waltham, MA
Monrovia, CA
Norfolk, VA
Seattle, WA
Oakland, CA
Sacramento, CA
Baltimore, MD
South Africa
Uganda
Lesotho
Kenya
Zimbabwe
US Funder: USAID
Health Area(s): HIV/AIDS, Women's health/reproductive health
The sudden shutdown of a USAID-funded malaria vaccine initiative disrupted an ongoing clinical trial, invalidated results, and set back progress toward more effective, longer-lasting vaccines.
— Information current as of March 2026
Location(s):
Seattle, WAWashington, DC
La Jolla, CA
Jupiter, FL
Baltimore, MD
Austin, TX
England
Denmark
US Funder: USAID
Health Area(s): Malaria